Company news

Novavax, Inc. news in 2023

Novavax, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

December 17, 2023

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada

December 4, 2023

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

November 27, 2023

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

November 16, 2023

Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights

November 8, 2023

Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023

November 1, 2023

Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

October 30, 2023

Novavax's Updated COVID-19 Vaccine Now Approved in the EU

October 30, 2023

Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore

October 17, 2023

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom

October 17, 2023

Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.

October 12, 2023

Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

October 10, 2023

Novavax Launches Choose to Protect™ Campaign to Educate Public About Importance of Updated COVID Vaccination this Fall

October 9, 2023

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

October 2, 2023

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

August 21, 2023

Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights

August 7, 2023

Novavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023

July 31, 2023

Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID

July 5, 2023

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

June 14, 2023

Novavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023

June 14, 2023

Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research

June 4, 2023

Novavax to Participate in the Jefferies Global Healthcare Conference

May 31, 2023

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

May 25, 2023

Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

May 11, 2023

Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses

May 8, 2023

Novavax Reports First Quarter 2023 Financial Results and Operational Highlights

May 8, 2023

Novavax to Participate in the BofA Securities 2023 Health Care Conference

May 3, 2023

Novavax to Host Conference Call to Discuss First Quarter 2023 Financial Results and Operational Highlights on May 9, 2023

May 1, 2023

Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases

April 3, 2023

Novavax to Participate in TD Cowen's 43rd Annual Health Care Conference

March 5, 2023

Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

February 27, 2023

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 28, 2023

February 20, 2023

U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

February 12, 2023

Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

January 17, 2023

Novavax Names John C. Jacobs as New President & Chief Executive Officer

January 8, 2023

Calls in 2023

Decks in 2023